CEA-based DNA vaccine exhibits promising antitumour activity
1
Inpharma 1317 - 8 Dec 2001 CEA-based DNA vaccine exhibits promising antitumour activity A DNA vaccine encoding human carcinoembryonic antigen (CEA) in conjunction with monoclonal antibody KS1-4-IL-2 conjugate exhibited promising antitumour activity against a CEA-expressing Lewis lung carcinoma (LLC-CEA-KSA) cell line in a murine model, report researchers from the US. In this study, CEA transgenic mice received a total of 3 oral immunisations at 2-week intervals, with a Salmonella typhimurium vector harbouring the active vaccine (containing the entire CEA human gene; pW- CEA) or an inactive control (pER-CEA). Unimmunised animals acted as another group of controls. All animals were challenged with a lethal dose of LLC-CEA-KSA cells injected either subcutaneously, or intravenously to induce pulmonary metastases, 2 weeks after the last immunisation. Selected animals also received IV monoclonal antibody KS1-4-IL-2 conjugate for 5 days, starting 24 hours after tumour challenge. Treatment with pW-CEA alone reduced SC tumour cell growth to approximately 25% of that seen in unimmunised controls, and prevented pulmonary metastases developing in 2 of 8 animals. However, combination therapy with pW-CEA and monoclonal antibody KS1-4-IL-2 conjugate resulted in complete regression of all SC tumours in all 8 animals and prevented the development of pulmonary metastases in 6 of 8 animals. Treatment with pER-CEA alone, or in combination with monoclonal antibody KS1-4-IL-2 conjugate, had no significant inhibitory effect when compared with unimmunised controls. The researchers conclude that these findings suggest that ‘combinations of DNA vaccines with such immunocytokines may lead to improved treatments for lung cancer’. Niethammer AG, et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine 20: 421-429, 12 Nov 2001 800885975 1 Inpharma 8 Dec 2001 No. 1317 1173-8324/10/1317-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of CEA-based DNA vaccine exhibits promising antitumour activity
Inpharma 1317 - 8 Dec 2001
CEA-based DNA vaccine exhibitspromising antitumour activity
A DNA vaccine encoding human carcinoembryonicantigen (CEA) in conjunction with monoclonal antibodyKS1-4-IL-2 conjugate exhibited promising antitumouractivity against a CEA-expressing Lewis lung carcinoma(LLC-CEA-KSA) cell line in a murine model, reportresearchers from the US.
In this study, CEA transgenic mice received a total of 3oral immunisations at 2-week intervals, with aSalmonella typhimurium vector harbouring the activevaccine (containing the entire CEA human gene; pW-CEA) or an inactive control (pER-CEA). Unimmunisedanimals acted as another group of controls. All animalswere challenged with a lethal dose of LLC-CEA-KSA cellsinjected either subcutaneously, or intravenously toinduce pulmonary metastases, 2 weeks after the lastimmunisation. Selected animals also received IVmonoclonal antibody KS1-4-IL-2 conjugate for 5 days,starting 24 hours after tumour challenge.
Treatment with pW-CEA alone reduced SC tumourcell growth to approximately 25% of that seen inunimmunised controls, and prevented pulmonarymetastases developing in 2 of 8 animals. However,combination therapy with pW-CEA and monoclonalantibody KS1-4-IL-2 conjugate resulted in completeregression of all SC tumours in all 8 animals andprevented the development of pulmonary metastases in6 of 8 animals. Treatment with pER-CEA alone, or incombination with monoclonal antibody KS1-4-IL-2conjugate, had no significant inhibitory effect whencompared with unimmunised controls.
The researchers conclude that these findings suggestthat ‘combinations of DNA vaccines with suchimmunocytokines may lead to improved treatments forlung cancer’.Niethammer AG, et al. An oral DNA vaccine against human carcinoembryonicantigen (CEA) prevents growth and dissemination of Lewis lung carcinoma inCEA transgenic mice. Vaccine 20: 421-429, 12 Nov 2001 800885975
1
Inpharma 8 Dec 2001 No. 13171173-8324/10/1317-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
![Classroom Embedded Assessment [CEA] Title: Particle Modellouisville.edu/education/centers/crimsted/cea-examples/grades-3-5-cea... · This CEA is administered at the beginning of a](https://static.fdocuments.us/doc/165x107/5e0c9c02fc643312e40fb808/classroom-embedded-assessment-cea-title-particle-this-cea-is-administered-at.jpg)
